[go: up one dir, main page]

WO2003059386A3 - Prion protein carrier-conjugates - Google Patents

Prion protein carrier-conjugates Download PDF

Info

Publication number
WO2003059386A3
WO2003059386A3 PCT/EP2003/000460 EP0300460W WO03059386A3 WO 2003059386 A3 WO2003059386 A3 WO 2003059386A3 EP 0300460 W EP0300460 W EP 0300460W WO 03059386 A3 WO03059386 A3 WO 03059386A3
Authority
WO
WIPO (PCT)
Prior art keywords
prion
provides
prion protein
conjugates
ordered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/000460
Other languages
French (fr)
Other versions
WO2003059386A2 (en
Inventor
Martin Bachmann
Patrick Maurer
Erica Pellicioli
Wolfgang A Renner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytos Biotechnology AG
Original Assignee
Cytos Biotechnology AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/050,902 external-priority patent/US7264810B2/en
Application filed by Cytos Biotechnology AG filed Critical Cytos Biotechnology AG
Priority to AU2003205623A priority Critical patent/AU2003205623A1/en
Publication of WO2003059386A2 publication Critical patent/WO2003059386A2/en
Publication of WO2003059386A3 publication Critical patent/WO2003059386A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular a prion peptide or prion protein-VLP-array. More specifically, the invention provides a composition comprising a virus-like particle and at least one prion protein (PrP) or a dimer thereof, or a PrP peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of prion diseases and as a pharmaccine to prevent or cure prion diseases and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
PCT/EP2003/000460 2002-01-18 2003-01-17 Prion protein carrier-conjugates Ceased WO2003059386A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003205623A AU2003205623A1 (en) 2002-01-18 2003-01-17 Prion protein carrier-conjugates

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US10/050,902 US7264810B2 (en) 2001-01-19 2002-01-18 Molecular antigen array
US10/050,902 2002-01-18
PCT/IB2002/000166 WO2002056905A2 (en) 2001-01-19 2002-01-21 Molecular antigen array
IBPCT/IB02/00166 2002-01-21
US39372502P 2002-07-08 2002-07-08
US60/393,725 2002-07-08
US39659002P 2002-07-18 2002-07-18
US60/396,590 2002-07-18

Publications (2)

Publication Number Publication Date
WO2003059386A2 WO2003059386A2 (en) 2003-07-24
WO2003059386A3 true WO2003059386A3 (en) 2004-03-11

Family

ID=27452011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/000460 Ceased WO2003059386A2 (en) 2002-01-18 2003-01-17 Prion protein carrier-conjugates

Country Status (2)

Country Link
AU (1) AU2003205623A1 (en)
WO (1) WO2003059386A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404126B2 (en) 2006-06-12 2016-08-02 Kuros Biosciences Ag Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234375D1 (en) 2001-09-14 2009-12-24 Cytos Biotechnology Ag PACKAGING IMMUNSTIMULATING CpG IN VIRUS LIKE PARTICLES: PREPARATION METHOD AND USE
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
JP5022028B2 (en) 2003-03-26 2012-09-12 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト Melan-A peptide analog-virus-like particle conjugate
PT1853285E (en) 2005-02-01 2011-06-06 Univ Ramot Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
JP5484732B2 (en) 2005-12-14 2014-05-07 サイトス バイオテクノロジー アーゲー Immunostimulatory nucleic acid package particles for the treatment of hypersensitivity
EP2895497B1 (en) * 2012-09-17 2017-11-22 F. Hoffmann-La Roche AG Method for the production of polypeptides in the periplasm of prokaryotic cells
EA035378B1 (en) 2015-01-15 2020-06-04 Юниверсити Оф Копенгаген Virus-like particle with efficient epitope display
EP3368068B1 (en) 2015-10-30 2020-11-18 University of Copenhagen Virus like particle with efficient epitope display

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032227A2 (en) * 1998-11-30 2000-06-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
WO2000078344A1 (en) * 1999-06-23 2000-12-28 Caprion Pharmaceuticals, Inc. Prion protein peptides and uses thereof
WO2001053457A2 (en) * 2000-01-21 2001-07-26 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
WO2001085208A2 (en) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
EP1158003A1 (en) * 2000-05-23 2001-11-28 Blood Transfusion Centre of Slovenia Antibodies capable to selectively detect prion PrP Sc isoforms

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032227A2 (en) * 1998-11-30 2000-06-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
WO2000078344A1 (en) * 1999-06-23 2000-12-28 Caprion Pharmaceuticals, Inc. Prion protein peptides and uses thereof
WO2001053457A2 (en) * 2000-01-21 2001-07-26 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
WO2001085208A2 (en) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
EP1158003A1 (en) * 2000-05-23 2001-11-28 Blood Transfusion Centre of Slovenia Antibodies capable to selectively detect prion PrP Sc isoforms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VASILJEVA I ET AL: "Mosaic Qbeta coats as a new presentation model", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 431, no. 1, 10 July 1998 (1998-07-10), pages 7 - 11, XP004258931, ISSN: 0014-5793 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404126B2 (en) 2006-06-12 2016-08-02 Kuros Biosciences Ag Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages

Also Published As

Publication number Publication date
AU2003205623A8 (en) 2003-07-30
WO2003059386A2 (en) 2003-07-24
AU2003205623A1 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
WO2004009124A3 (en) Ghrelin-carrier conjugates
CY1111751T1 (en) COMPOSITION OF VACCINES CONTENTS OF AMYLOIDA BETA ANTIGENOUS PROVISIONS 1-6
WO2003039225A3 (en) Antigen arrays comprising rankl for treatment of bone disease
PL369863A1 (en) Antigen arrays for treatment of allergic eosinophilic diseases
WO2002056905A3 (en) Molecular antigen array
WO2006063974A3 (en) Il-15 antigen arrays and uses thereof
PL392964A1 (en) Hyperimmune serum reactive antigen, the use of this antigen for the production of a pharmaceutical formulation, fragment of the hiperimmune antigen, antigen auxiliary epitopes, a vaccine containing the hyperimmune serum reactive antigen, formulation containing antibodies, process for the preparation of this formulation, the use of the formulation for the treatment of staphylococcal infections, and screening method
WO2006045796A3 (en) Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
WO2004007538A3 (en) Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
WO2005117983A3 (en) Carrier conjugates of tnf-peptides
WO2003059386A3 (en) Prion protein carrier-conjugates
WO2006027300A3 (en) Carrier conjugates of gnrh-peptides
MXPA04003901A (en) Antigen arrays presenting il-5, il-3 or eotaxin for treatment of allergic eosinophilic diseases.
MXPA04003900A (en) Antigen arrays for treatment of bone disease.
WO2007039458A3 (en) Hiv peptide conjugates and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP